Visão geral da empresa
A clinical-stage biotechnology enterprise, Replimune Group, Inc. is dedicated to the development and commercialization of oncolytic immunotherapies specifically designed to activate the immune system against cancer. This company operates within the broader Healthcare sector and the specialized Biotechnology industry, positioning itself to leverage advancements in immunology for oncological treatments. The organization employs a workforce of 479 individuals and maintains a total market capitalization of $596.17M. The absence of reported annual revenue in the provided data, combined with a market cap of $596.17M, suggests the company is in a pre-revenue or clinical-stage phase where valuation is driven primarily by asset potential and research pipeline rather than current sales performance.
Saúde financeira
The company reports no annual revenue for the trailing twelve months, a net income loss of $-314,852,992, and an EBITDA of $-318,880,992, indicating a significant gap between top-line activity and bottom-line profitability typical of early-stage biotechnology firms where research and development expenses outweigh any generated income. Free cash flow stands at $-172,752,880, reflecting a substantial cash outflow required to fund ongoing clinical trials and operational expenses, which limits immediate financial flexibility but is necessary for pipeline progression. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, a figure that in this context indicates the company has not yet generated commercial sales to establish a profit margin structure. Regarding liquidity and leverage, Replimune holds $269.14M in cash against $76.35M in debt, resulting in a debt-to-equity ratio of 36.26, which suggests a balance sheet structure that relies heavily on cash reserves to service obligations and fund operations rather than being highly leveraged. The current ratio is 5.60, a metric that signifies strong short-term liquidity and the ability to cover current liabilities with current assets well more than five times over. Finally, the return on equity is -90.9% and the return on assets is -43.2%, metrics that reveal that management has not yet generated positive returns on capital deployment, a common characteristic for companies in the clinical-stage biotechnology sector before commercialization begins.
Avaliação de valorização
The trailing P/E ratio is listed as N/A due to the lack of net income, while the forward P/E is calculated at -3.60, a valuation metric that implies the market is pricing in future earnings recovery but currently values the stock based on a multiple of negative earnings expectations. The price-to-book ratio is 2.73, indicating that the market values the company at a premium of 2.73 times its book value, which often reflects investor optimism regarding the potential value of intangible assets like intellectual property and clinical data. The price-to-sales ratio and EV/EBITDA are both N/A or negative (-1.26), suggesting that traditional sales-based or earnings-based valuation multiples are not applicable given the current financial structure of the biotechnology firm. The stock has traded with a 52-week high of $13.24 and a 52-week low of $2.68, placing the current valuation within a wide historical range that underscores the high volatility inherent in biotechnology equities. The beta value is 0.77, which indicates that the stock price exhibits lower volatility relative to the broader market, moving less aggressively than the overall index despite the sector's typical risk profile.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, meaning there is no historical growth rate to compare against one another within the provided data timeframe. Since the company does not pay dividends, the dividend yield and payout ratio are both N/A and 0.0% respectively, indicating that all available earnings, if any, or remaining cash reserves are retained within the company to fund research and development rather than being distributed to shareholders. The absence of a dividend payout ratio confirms that the company follows a strategy of reinvesting its financial resources into its clinical-stage product candidates and operational growth rather than providing regular income to investors. Consequently, the overall growth and income profile of Replimune Group, Inc. is characterized by a lack of current earnings growth or dividend income, relying entirely on capital markets and cash reserves to sustain operations and advance its immunotherapy pipeline toward potential commercialization.